EGM
OKUR

Engineers Gate Manager’s OnKure Therapeutics OKUR Stock Holding History

Engineers Gate Manager’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,684
Closed -$58.9K – 2366
2023
Q4 		$58.9K Buy
+3,684
New +$230K ﹤0.01% 1829

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Engineers Gate Manager's OKUR Position: Q1 2024 in Review

Engineers Gate Manager sold out of OnKure Therapeutics (OKUR) in Q1 2024, closing a stake of 3,684 shares — an estimated $58.9K sold.

Engineers Gate Manager first reported a position in OKUR in Q4 2023 and held it in 1 quarter. The position peaked at $58.9K in Q4 2023. 61 funds tracked by Wall St. Rank hold OKUR as of Q1 2024.

  • Engineers Gate Manager reported no remaining OnKure Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Engineers Gate Manager sold 3,684 OnKure Therapeutics shares in Q1 2024, an estimated $58.9K.
  • Engineers Gate Manager first reported a position in OnKure Therapeutics in Q4 2023 and held it in 1 quarter.
  • Engineers Gate Manager's OnKure Therapeutics position peaked at $58.9K in Q4 2023.
  • 61 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2024.

Based on Engineers Gate Manager's 13F filing for Q1 2024, filed 15 May 2024.